Abstract
Aim: This prospective, Phase III study assessed the pharmacokinetics (PK), safety and tolerability of immune globulin subcutaneous, human – klhw 20% solution (IGSC-C 20%) in participants with prima... Lay abstract This clinical trial studied a new US FDA-approved product, immune globulin subcutaneous, human – klhw 20% solution (IGSC-C 20%), to treat primary humoral immunodeficiency (PI), a group...
Funding Information
  • Grifols
  • Research Triangle Park, NC, USA
  • Green Cross
  • Therapure
  • Kedrion and Prometic
  • Adverum
  • BioCryst
  • CSL Behring
  • Optinose
  • Shire
  • Attenua
  • BioCryst
  • CSL Behring
  • Takeda Pharmaceuticals

This publication has 25 references indexed in Scilit: